Abstract
Colorectal cancer accounts for about 15% of all cancers in the United States. FDG-PET is used most frequently for restaging in patients who present with rising tumor markers or some equivocal finding on anatomical imaging or who are symptomatic after primary treatment has been completed. The ability of FDG-PET to determine extra-hepatic disease involvement can be limited by physiologically increased mucosal FDG uptake. PET/CT is especially useful for these cases. Further, PET/CT facilitates the characterization of small, mildly hyper-glycolytic liver lesions. This can be difficult with PET alone because of the relatively high physiological hepatic glycolytic activity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Colorectal Cancer
Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, Marchai G, Filez L, Aerts R. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995; 21(5):517–522.
Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41(7): 1177–1189.
Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, Phelps ME, Valk P, Czernin J. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med. 2001;42(4):586–590.
Esophageal Cancer
Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, Meltzer CC. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999;68(4):1133–1136.
Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D, Mortelmans L. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000;120(6): 1085–1092.
Pancreatic Cancer
Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, Beger HG. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic cancer. J Nucl Med. 1997;38(9):1344–1348.
Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, Sontheimer J, Farthmann EH. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg. 1999;86(2):194–199.
Fröhlich A, Diederichs CG, Staib L, Vogel J, Berger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med. 1999;40(2):250–255.
Rose D, Delbeke D, Beauchamp R, Chapman WC, Sandler MP, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999; 229:729–737.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Czernin, J., Dahlbom, M., Ratib, O., Schiepers, C. (2004). Cancers of the Gastrointestinal Tract. In: Atlas of PET/CT Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18517-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-18517-5_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62141-3
Online ISBN: 978-3-642-18517-5
eBook Packages: Springer Book Archive